GlassScriptPhysician profile
Pradeesh Mahendran
NPI 1780243808
$6,683.22
in general payments reported to CMS, 2019-2025
38 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $512 · 2023: $2,423 · 2024: $1,911 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,171.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,697.97 | 2023-2025 | |
| Glaxosmithkline, LLC. | $1,069.36 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $845.38 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $544.30 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $409.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $271.78 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $168.90 | 2024-2025 | Repatha, Otezla, Evenity |
| Edwards Lifesciences Corporation | $153.14 | 2022 | |
| Janssen Pharmaceuticals, INC | $145.38 | 2023-2024 | Xarelto |
| Antares Pharma, INC. | $140.63 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Phathom Pharmaceuticals, INC. | $103.87 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.02 | 2023-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.35 | 2025 | Caplyta |
| Corcept Therapeutics | $77.28 | 2023 | Korlym |
| Verona Pharma, INC. | $63.03 | 2025 | Ohtuvayre |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $58.40 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.78 | 2022 | |
| Axsome Therapeutics, INC. | $57.60 | 2023-2025 | Auvelity |
| Corium, LLC | $54.75 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $51.67 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $51.00 | 2024 | Eliquis |
| Neurocrine Biosciences, INC. | $46.28 | 2023-2024 | Ingrezza |
| Alkermes, INC. | $42.72 | 2023 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $41.33 | 2023 | Belbuca, Xtampza |
| Otsuka America Pharmaceutical, INC. | $38.52 | 2024 | Rexulti |
| Pfizer INC. | $38.28 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $35.66 | 2024-2025 | Austedo Xr, Austedo Xr |
| Merck Sharp & Dohme LLC | $33.91 | 2023-2024 | Belsomra, Gardasil, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.22 | 2023-2024 | Xifaxan, Relistor |
| Abbott Laboratories | $26.34 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Halozyme INC | $19.56 | 2023 | |
| Dynavax Technologies Corporation | $18.72 | 2023 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $18.59 | 2023 | Trintellix |
| Emd Serono, INC. | $18.03 | 2024 | |
| Xeris Pharmaceuticals, INC. | $16.28 | 2023 | Gvoke Hypopen |
| Indivior INC. | $15.60 | 2023 | Sublocade |
| Impel Pharmaceuticals INC. | $14.78 | 2023 | Trudhesa |
| Ibsa Pharma INC. | $14.62 | 2025 | Flector, Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeesh Mahendran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.